Loading clinical trials...
Loading clinical trials...
A Phase 3, Randomized, Double-Blind, Placebo Controlled, Multi-Center Trial to Evaluate the Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines (SAKURA-1)
Conditions
Interventions
Botulinum Toxins, Type A
Placebos
Locations
15
United States
Birmingham, Alabama, United States
Beverly Hills, California, United States
Newport Beach, California, United States
San Francisco, California, United States
Santa Monica, California, United States
Greenwood, Colorado, United States
Start Date
December 8, 2016
Primary Completion Date
November 14, 2017
Completion Date
November 14, 2017
Last Updated
July 21, 2022
NCT05481931
NCT06411002
NCT05146999
NCT05148000
NCT05277337
NCT04249583
Lead Sponsor
Revance Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions